港股收評:恆指漲1.7%上揚近300點 內房股與物管股全天領漲
格隆匯11月14日丨港股全天保持強勢行情,三大指數午後略有回落,但最終全線收漲,延續上週反彈行情。恆指漲1.7%上揚近300點,國指漲1.92%,6000點得而復失,恆生科技指數一度大漲4.5%,收漲1.8%,三者均收假陰線。盤面上,大型科技股部分衝高回落明顯,美團、快手跌近2%,盤初一度漲超4%,京東、百度、騰訊漲幅收窄;房地產支持政策不斷,內房股與物管股攜手大漲,碧桂園盤中一度飆漲超50%,龍光集團、富力地產等漲幅居市場前列;醫藥類股持續活躍,互聯網醫療股領銜上揚,中醫藥股午後漲幅擴大。另一方面,在線教育股逆勢下跌,新東方重挫逾11%表現最差,航空股尾盤跌勢明顯擴大,豬肉概念股、蘋果概念股普跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.